Poisoning Pyridoxal 5-Phosphate-Dependent Enzymes: A New Strategy to Target the Malaria Parasite Plasmodium falciparum
Ingrid B. Müller, Fang Wu, Bärbel Bergmann et al. · 2009
Read Poisoning Pyridoxal 5-Phosphate-Dependent Enzymes: A New Strategy to Target the Malaria Parasite Plasmodium falciparum by Ingrid B. Müller, Fang Wu, Bärbel Bergmann et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0004406.txt.
Introduction
Malaria parasites make a vitamin cofactor they cannot live without. Ingrid Müller, Fang Wu, Bärbel Bergmann, and co-authors target that pathway in this 2009 PLOS ONE article. The parasite Plasmodium falciparum synthesizes pyridoxal 5-phosphate during its blood stage.
The parasite also has an enzyme to activate B6 vitamins salvaged from the host. The authors propose poisoning PLP-dependent enzymes as a new strategy against the parasite. Hitting a cofactor the parasite must make or activate could yield new drugs. Fresh targets matter as resistance spreads. Enzymes that need PLP span many pathways, widening the strategy's possible reach.
Catalog record
| CREATOR | Ingrid B. Müller, Fang Wu, Bärbel Bergmann et al. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004406
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Poisoning Pyridoxal 5-Phosphate-Dependent Enzymes: A New Strategy to Target the Malaria Parasite Plasmodium falciparum Authors: Ingrid B. Müller, Fang Wu, Bärbel Bergmann, Julia Knöckel, Rolf D. Walter, Heinz Gehring, Carsten Wrenger Published: 2009, PLOS ONE DOI: 10.1371/journal.pone.0004406 ABSTRACT The human malaria parasite Plasmodium falciparum is able to synthesize de novo pyridoxal 5-phosphate (PLP), a crucial cofactor, during erythrocytic schizogony. However, the parasite possesses additionally a pyridoxine/pyridoxal kinase (PdxK) to activate B6 vitamers salvaged from the host. We describe a strategy whereby synthetic pyridoxyl-amino acid adducts are channelled into the parasite. Trapped upon phosphorylation by the plasmodial PdxK, these compounds block PLP-dependent enzymes and thus impair the growth of P. falciparum . The novel compound PT3, a cyclic pyridoxyl-tryptophan methyl ester, inhibited the proliferation of Plasmodium very efficiently (IC 50 -value of 14 µM) without harming human cells. The non-cyclic pyridoxyl-tryptophan methyl ester PT5 and the pyridoxyl-histidine methyl ester PHME were at least one order of magnitude less effective or completely ineffective in the case of the latter. Modeling in silico indicates that the phosphorylated forms of PT3 and PT5 fit well into the PLP-binding site of plasmodial ornithine decarboxylase ( Pf ODC), the key enzyme of polyamine synthesis, consistent with the ability to abolish ODC activity in vitro . Furthermore, the antiplasmodial effect of PT3 is directly linked to the capability of Plasmodium to trap this pyridoxyl analog, as shown by an increased sensitivity of parasites overexpressing Pf PdxK in their cytosol, as visualized by GFP fluorescence. INTRODUCTION Malaria is one of the most threatening diseases in the world, with more than 300 million infected people and up to 2 million fatalities annually, mainly young children and pregnant women living in Africa. The causative agent of the most severe form, tropical malaria, is Plasmodium falciparum, a protozoan parasite that sequesters in the red blood cells of its human host. As yet, there are no vaccines available and the few antimalarials are losing their efficacy due to the rapid spread of drug-resistant parasites. There is therefore an urgent need to find new strategies to interfere with the parasite's metabolism. Pyridoxal 5-phosphate (PLP) is the active form of vitamin B6, which comprises the vitamers pyridoxine, pyridoxal and pyridoxamine as well as their related phosphate esters. It is a crucial cofactor for various enzymatic reactions, predominantly involved in the transformation of amino acids [1] . Many of the PLP-dependent enzymes are essential and therein offer the possibility to target diseases [2] . There are already promising attempts, such as the inhibition of γ-aminobutyric acid (GABA) aminotransferase by vigabatrin in epilepsy therapy [3] or of alanine racemase by antibacterial agents [4] , [5] . The PLP-dependent enzyme ornithine decarboxylase (ODC) is a target in the fight against African trypanosomes, the causative agent of sleeping sickness, and against cancer [2] , [6] , [7] . ODC is the key enzyme in the formation of polyamines, which are essential for cellular proliferation and differentiation [8] , [9] , and accordingly, polyamine biosynthesis in the malaria parasite is also considered to be a possible drug target [10] . The reactions of PLP-dependent enzymes are highly diverse; however the initial formation of a Schiff base of PLP with the amino group of an amino acid is a common intermediate to all of them. Reduction of the Schiff base leads to a covalent coenzyme-substrate adduct resembling a transition-state analog with high affinity to the apoprotein [11] . Over thirty years ago, Heller et al. [12] synthesized several phosphopyridoxyl-amino acids that mimic the Schiff base intermediate involved in enzymatic decarboxylation. Among these, N-(5-phosphopyridoxyl)-ornithine inhibited rat liver ODC by binding to the holoenzyme in a non-competitive manner with respect to substrate and cofactor. Recently, a new analog, the BOC-protected pyridoxyl-ornithine conjugate (POB), was shown to inhibit human ODC in cells as well as the growth of various tumor and transformed cells effectively, whereas non-tumorigenic cells were less affected [13] . Another analog, pyridoxyl-histidine methyl ester (PHME), was able to inhibit human histidine decarboxylase in human mastocytoma cells without affecting proliferation [14] . Plants, bacteria, as well as some fungi are able to synthesize PLP de novo , whereas mammals entirely depend on the dietary uptake of pyridoxal, pyridoxine and pyridoxamine. They are converted into PLP via phosphorylation by pyridoxal/pyridoxine kinase (PdxK; EC 2.7.1.35) and subsequent oxidation by pyridoxine/pyridoxamine oxidase (EC 1.4.3.5). Although PdxK is widely distributed in human tissues, oxidase activity is low or absent in most cells [15] . Human erythrocytes have both enzymes and are proposed to be the main carrier of vitamin B6. PLP in red blood cells is mostly bound to proteins. To provide tissues with pyridoxal, PLP is dephosphorylated by vitamin B6 specific phosphatase within the erythrocyte [16] . The plasmodial parasite generates vitamin B6 de novo in its erythrocytic stage [17] , [18] . The assembly of the plasmodial PLP-synthesis machinery follows a hierarchically defined course, which seems to be essential for activity [19] . In addition, the parasite possesses a functional PdxK [17] , which in other protozoan parasites that lack de novo synthesis, such as trypanosomes, is the only enzyme activating salvaged pyridoxal [20] . In this report we present a new approach to target the malaria parasite by designing and testing novel pyridoxyl-adducts as antimalarials. In a first step these compounds are trapped upon phosphorylation in the parasite. In this state they mimic PLP and together with the substrate moiety they bind and inhibit efficiently PLP-dependent enzymes, which eventually kills the parasite. We validate their potency as substrates of Pf PdxK as well as their inhibitory effect on the PLP-dependent enzyme Pf ODC, and finally we demonstrate that the antiplasmodial effect can be directly linked to the activity of the plasmodial PdxK as transgenic parasites overexpressing Pf PdxK exhibit an increased sensitivity towards the pyridoxyl-analog. RESULTS Our strategy is based on the fact that pyridoxal is phosphorylated by the plasmodial PdxK and the resulting PLP is thereby trapped within the parasite. In this respect the non-phosphorylated pyridoxyl-adducts PT3, PT5 and PHME (shown in Figure 1 ; their synthesis and that of their phosphorylated forms is described in the section Supporting information, Text S1 ) were tested as potential substrates of Pf PdxK. All three pyridoxyl-adducts were phosphorylated by the plasmodial enzyme with specific activities of 38, 20 and 64 nmol min −1 mg −1 , respectively ( Table 1 ). The phosphorylation sites are indicated by arrows. All results represent the mean values±standard deviations of three to six independent experiments; n. d. = not detectable. Values are taken from [17] . TABLE: PT3, PT5, PHME and their phosphate esters as substrates of Pf PdxK or inhibitors of Pf ODC Compounds Specific activity of Pf PdxK (nmol min −1 mg −1 ) a) Inhibition of Pf ODC activity IC 50 -value [µM] a) PHME 64±4 n.d. PT5 20±2 n.d. PT3 38±4 n.d. PPHME n.d. 58±11 PPT5 n.d. 64±13 Pyridoxine b) 112±9 Pyridoxal b) 50±4 Pyridoxamine b) 30±2 PHOSPHORYLATED PYRIDOXYL-AMINO ACIDS INHIBIT PF ODC IN VITRO Phosphorylation of pyridoxal is required in order to obtain the active cofactor for the enzymatic reaction of PLP-dependent enzymes. The activity of ODC depends on PLP and its competition by the pyridoxyl-adducts was measured as a representative for